Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA)

Clinical Rheumatology

Volumn 36, Issue 4, 2017, Pages 773-779

  Iannone, Florenzo ^a   Courvoisier, Delphine S ^b   Gottenberg, Jacques Eric ^c   Hernandez, Maria Victoria ^d   Lie, Elisabeth ^e   Canhão, Helena ^f   Pavelka, Karel ^g   Hetland, Merete Lund ^h,i   Turesson, Carl ^j,k   Mariette, Xavier ^l   Choquette, Denis ^m   Finckh, Axel ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d HOSPITAL CLÍNIC   (Spain)

^e DIAKONHJEMMET HOSPITAL   (Norway)

^f HOSPITAL DE SANTA MARIA   (Portugal)

^g CHARLES UNIVERSITY   (Czech Republic)

^h GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j LUND UNIVERSITY   (Sweden)

^k LUND UNIVERSITY HOSPITAL   (Sweden)

^l INSERM   (France)

^m CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

Abatacept; Body mass index; Drug survival; Rheumatoid arthritis

Indexed keywords

ABATACEPT; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DRUG EFFICACY; DRUG RETENTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MEDIAN SURVIVAL TIME; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT INTERRUPTION; UNDERWEIGHT; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; EUROPE; KAPLAN MEIER METHOD; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGISTER; REMISSION; TREATMENT OUTCOME;

ABATACEPT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BODY MASS INDEX; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; REMISSION INDUCTION; RHEUMATOID FACTOR; TREATMENT OUTCOME;

EID: 85003864879     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3505-5     Document Type: Article

References (35)

1. Lu B, Hiraki LT, Sparks JA, Malspeis S, Chen CY, Awosogba JA et al (2014) Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis 73:1914–1922
2. Ajeganova S, Andersson ML, Hafström I, BARFOT Study Group (2013) Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res (Hoboken) 65:78–87
3. Baker JF, Ostergaard M, George M, Shults J, Emery P, Baker DG, Conaghan PG (2014) Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years. Ann Rheum Dis 73:1923–1928
4. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW (2008) A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 67:769–774
5. Westhoff G, Rau R, Zink A (2007) Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 56:3575–3582
6. Humphreys JH, Verstappen SM, Mirjafari H, Bunn D, Lunt M, Bruce IN, Symmons DP (2013) Association of morbid obesity with disability in early inflammatory polyarthritis: results from the Norfolk arthritis register. Arthritis Care Res (Hoboken) 65:122–126
7. Finckh A, Turesson C (2014) The impact of obesity on the development and progression of rheumatoid arthritis. Ann Rheum Dis 73:1911–1913
8. Turesson C, Bergström U, Pikwer M, Nilsson JÅ, Jacobsson LT (2016) A high body mass index is associated with reduced risk of rheumatoid arthritis in men, but not in women. Rheumatology (Oxford) 55:307–314
9. Iannone F, Lapadula G (2010) Obesity and inflammation—targets for OA therapy. Curr Drug Targets 11:586–598
10. Iannone F, Lapadula G (2011) Chemerin/ChemR23 pathway: a system beyond chemokines. Arthritis Res Ther 13:104
11. Wang QP, Li XP, Wang M, Zhao LL, Li H, Xie H, Lu ZY (2014) Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: an in vivo study. Endocrine 47:845–853
12. Ellerby N, Mattey DL, Packham J, Dawes P, Hider SL (2014) Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis 73:74
13. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR et al (2013) Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 65:94–100
14. Heimans L, van den Broek M, le Cessie S, Siegerink B, Riyazi N, Han KH et al (2013) Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 65:1235–1242
15. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP (2011) Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63:359–364
16. Rodrigues AM, Reis JE, Santos C, Pereira MP, Loureiro C, Martins F et al (2014) A1.1 obesity is a risk factor for worse treatment response in rheumatoid arthritis patients—results from reuma.pt. Ann Rheum Dis 73(Suppl 1):A1
17. Sandberg ME, Bengtsson C, Källberg H, Wesley A, Klareskog L, Alfredsson L, Saevarsdottir S (2014) Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 73:2029–2033
18. Iannone F, Fanizzi R, Notarnicola A, Scioscia C, Anelli MG, Lapadula G (2015) Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. Joint Bone Spine
19. Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT et al (2014) Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord 15:14
20. Finckh, Neto, Iannone, Loza, Lie, van Riel et al. (2015) The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open 1. doi:10.1136/rmdopen
21. Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J et al (2015) The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford) 54:1074–1079
22. Fransen J, van Riel PL (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin N Am 35:745–757 vii-viii
23. Kristensen LE, Saxne T, Geborek P (2006) The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 54:600–606
24. Nüßlein H, Alten R, Galeazzi M, Lorenz HM, Nurmohame MT, Bensen WG, Burmester G (2014) Does body mass index impact long-term retention with abatacept in patients with RA who have received at least one prior biologic agent. 2-year results from a real-world, international, prospective study. Arthritis Rheum 66S:2492
25. Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H et al. (2016) Rheumatoid factor and anti-citrullinated protein antibody positivity are associated with a better effectiveness of abatacept: results from the Pan-European registry analysis. Arthritis Rheumatol
26. De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R, MIRA Study Group (2014) Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in rheumatoid arthritis registry. J Rheumatol 41:1761–1765
27. Ottaviani S, Gardette A, Roy C, Tubach F, Gill G, Palazzo E et al (2015) Body mass index and response to rituximab in rheumatoid arthritis. Joint Bone Spine 82:432–436
28. Pers YM, Godfrin-Valnet M, Lambert J, Fortunet C, Constant E, Mura T et al (2015) Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol 42:580–584
29. Gardette A, Ottaviani S, Sellam J, Berenbaum F, Lioté F, Meyer A et al. (2016) Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol
30. D'Agostino MA, Le Bars M, Taylor M, Chou B, Zhu J, Ranganath VK (2015) In patients with rheumatoid arthritis and an inadequate response to methotrexate, does body mass index influence the efficacy of abatacept on inflammation when measured by power doppler ultrasonography? Results from the APPRAISE study. Ann Rheum Dis 74S2:231
31. Gardette A, Ottaviani S, Sellam J, Berenbaum F, Lioté F, Fautrel B et al. (2016) Body mass index and response to abatacept in rheumatoid arthritis. Eur J Clin Invest
32. Corbo, Valencia, Raymond, Agrawal, Townsend, Zhou et al (2009) Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity. Ann Rheum Dis 68(S3):574
33. Roy A, Mould DR, Wang XF, Tay L, Raymond R, Pfister M (2007) Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol 47:1408–1420
34. Alten R, Nublein HG, Galeazzi M, Lorenz H-M, Mariette X, Cantagrel A et al (2015) Body mass index does not influence the efficacy of abatacept in patients with RA who are biologic Naïve: 6-month results from a real-world, international, prospective study. Arthritis Rheum 67S:553
35. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509